Evonik Full-Year Report 2023

A Challenging Year

  • Lower demand as a result of the weak economic environment
  • Selling prices stable in the specialty chemicals businesses but significant declines at Animal Nutrition and Performance Intermediates
  • Sales decreased by 17 percent to €15.3 billion, mainly due to volumes
  • Adjusted EBITDA fell 33 percent to €1.7 billion
  • High free cash flow of €801 million
  • Adjusted net income 65 percent below the prior-year level at €370 million
  • Net income was -€465 million as a consequence of high impairment losses
  • Outlook for 2024: adjusted EBITDA expected to be between €1.7 billion and €2.0 billion

Free Trial

Step 1 of 2

Name(Required)

By pressing “Send” you agree to the Privacy Policy of this site

No Credit Card needed, after filling up the form you will receive your Free-Trial login information in 24 to 48 hours by e-mail.

ImprintPrivacy Policy

All Rights Reserved © aicorite.com